Cancer Therapy
Pharmaceutical Sciences
Raman Bahal
Associate Professor/Pharmaceutical Science

Are you Raman Bahal?

How to update your information.
Grants

20 Grants

Developing next generation synthetic nucleic acid analogous for sickle cell disease
Sponsor: DHHS/NIH/National Heart, Lung, and Blood Institute
Authors: Raman Bahal
Funding: $2,000,300
2019-12-15 - 2025-11-30
Targeting microRNAs to the tumor microenvironment with pHLIP conjugated next generation chemically modified PNAs
Sponsor: DHHS/NIH/National Cancer Institute/Beth Israel Deaconess Medical Center
Authors: Raman Bahal
Funding: $886,089
2020-02-07 - 2025-01-31
Targeted delivery of chemically modified RNA inhibitors for prostate cancer therapy
Sponsor: DHHS/NIH/National Institutes of Health/Eastern Virginia Medical School
Authors: Raman Bahal
Funding: $0
2025-04-01 - 2030-03-31
Evaluation of LNPs for Pulmonary Delivery
Sponsor: Gatehouse Bio
Authors: Raman Bahal
Funding: $0
2025-02-01 - 2025-07-30
Engineered gamma-peptide nucleic acids to inhibit miR-122-mediated diabetes and diabetic vasculopathy
Sponsor: DHHS/NIH/National Heart, Lung, and Blood Institute/University of Iowa
Authors: Raman Bahal
Funding: $0
2025-07-01 - 2028-06-30
Treatment of Lung Fibrosis by Pulmonary Delivery of Advanced Anti-miRs in Nanoparticles
Sponsor: DHHS/NIH/National Institutes of Health/Yale University
Authors: Raman Bahal
Funding: $0
2024-09-01 - 2029-08-31
Development of Dual peptide tagged nanoparticle delivery system for the treatment of stroke
Sponsor: American Heart Association/University of Connecticut Health Center
Authors: Raman Bahal
Funding: $0
2025-07-01 - 2027-06-30
Next-generation microRNA inhibitors for urological malignancy
Sponsor: DHHS/NIH/National Institutes of Health/Eastern Virginia Medical School
Authors: Raman Bahal
Funding: $0
2025-12-01 - 2030-11-30
Kidney-targeted chemically modified glycoconjugates-based RNA therapeutics for ADPKD
Sponsor: DHHS/NIH/National Institutes of Health/Yale University
Authors: Raman Bahal
Funding: $0
2025-12-01 - 2030-11-30
Targeting Microbial Enzymes to Mitigate Heart Failure: The Role of Tryptophan Decarboxylases
Sponsor: American Heart Association/University of Iowa
Authors: Raman Bahal
Funding: $0
2025-07-01 - 2028-06-30
Nanoparticles with chemically modified PNAs targeting multiple oncomiRs for brain tumor
Sponsor: DHHS/NIH/National Cancer Institute/Yale University
Authors: Raman Bahal
Funding: $0
2025-07-01 - 2030-06-30
Sequence-specific inhibition of c-Myc in vivo by next-generation nucleic acid analogs
Sponsor: DHHS/NIH/National Institute of General Medical Sciences
Authors: Raman Bahal
Funding: $0
2025-07-01 - 2030-06-30
Developing next-generation RNA inhibitors for stroke therapy
Sponsor: DHHS/NIH/National Institute of Neurological Disorders and Stroke/University of Connecticut Health Center
Authors: Raman Bahal
Funding: $0
2025-07-01 - 2030-06-30
Kidney targeted RNA therapies for ADPKD
Sponsor: DHHS/NIH/National Institutes of Health/Yale University School of Medicine
Authors: Raman Bahal
Funding: $0
2025-04-01 - 2030-03-31
Developing a Sequence-Specific VEGFA Genomic DNA Inhibitor for Cancer Therapy
Sponsor: DHHS/NIH/National Institutes of Health
Authors: Raman Bahal
Funding: $0
2025-12-01 - 2027-11-30
Endothelium-targeted gamma-peptide nucleic acids to inhibit miR-122-mediated diabetic vasculopathy
Sponsor: DHHS/NIH/National Heart, Lung, and Blood Institute/University of Iowa
Authors: Raman Bahal
Funding: $0
2025-04-01 - 2030-03-31
Targeted disruption of STAT3 hypertranscription for cancer therapy
Sponsor: DHHS/NIH/National Institutes of Health
Authors: Raman Bahal
Funding: $0
2025-04-01 - 2030-03-31
Targeting DNA-PK Inhibitors to the Tumor Microenvironment by pHLIP
Sponsor: DHHS/NIH/National Institutes of Health/Yale University
Authors: Raman Bahal
Funding: $0
2024-09-01 - 2029-08-31
Developing next-generation chemically modified miRNA inhibitors for cancer and immune therapy
Sponsor: DHHS/NIH/National Institutes of Health/Beth Israel Deaconess Medical Center
Authors: Raman Bahal
Funding: $0
2025-04-01 - 2030-03-31
Advancing Stroke Treatment with yPNA-Based miR-141-3p Inhibitors
Sponsor: American Heart Association/University of Connecticut Health Center
Authors: Raman Bahal
Funding: $0
2025-07-01 - 2028-06-30